These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Cabozantinib as an emerging treatment for sarcoma. Schöffski P; Blay JY; Ray-Coquard I Curr Opin Oncol; 2020 Jul; 32(4):321-331. PubMed ID: 32541320 [TBL] [Abstract][Full Text] [Related]
7. Phase II study of cediranib in patients with advanced gastrointestinal stromal tumors or soft-tissue sarcoma. Judson I; Scurr M; Gardner K; Barquin E; Marotti M; Collins B; Young H; Jürgensmeier JM; Leahy M Clin Cancer Res; 2014 Jul; 20(13):3603-12. PubMed ID: 24714778 [TBL] [Abstract][Full Text] [Related]
8. Current Molecular Targeted Therapies for Bone and Soft Tissue Sarcomas. Nakano K; Takahashi S Int J Mol Sci; 2018 Mar; 19(3):. PubMed ID: 29510588 [TBL] [Abstract][Full Text] [Related]
9. Cost effectiveness of tyrosine kinase inhibitor therapy in metastatic gastrointestinal stromal tumors. Blanke CD; Huse DM J Med Econ; 2010; 13(4):681-90. PubMed ID: 21067355 [TBL] [Abstract][Full Text] [Related]
10. Receptor Tyrosine Kinase Inhibitors for the Treatment of Recurrent and Unresectable Bone Sarcomas. Albarrán V; Villamayor ML; Chamorro J; Rosero DI; Pozas J; San Román M; Calvo JC; Pérez de Aguado P; Moreno J; Guerrero P; González C; García de Quevedo C; Álvarez-Ballesteros P; Vaz MÁ Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430263 [TBL] [Abstract][Full Text] [Related]
11. Novel targeted therapies in the treatment of soft-tissue sarcomas. Chao J; Chow WA; Somlo G Expert Rev Anticancer Ther; 2010 Aug; 10(8):1303-11. PubMed ID: 20735315 [TBL] [Abstract][Full Text] [Related]
12. [Medical treatment of soft tissue sarcomas based on the histological subtype]. Pápai Z Magy Onkol; 2014 Mar; 58(1):53-8. PubMed ID: 24712007 [TBL] [Abstract][Full Text] [Related]
13. Time to Definitive Failure to the First Tyrosine Kinase Inhibitor in Localized GI Stromal Tumors Treated With Imatinib As an Adjuvant: A European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Intergroup Randomized Trial in Collaboration With the Australasian Gastro-Intestinal Trials Group, UNICANCER, French Sarcoma Group, Italian Sarcoma Group, and Spanish Group for Research on Sarcomas. Casali PG; Le Cesne A; Poveda Velasco A; Kotasek D; Rutkowski P; Hohenberger P; Fumagalli E; Judson IR; Italiano A; Gelderblom H; Adenis A; Hartmann JT; Duffaud F; Goldstein D; Broto JM; Gronchi A; Dei Tos AP; Marréaud S; van der Graaf WT; Zalcberg JR; Litière S; Blay JY J Clin Oncol; 2015 Dec; 33(36):4276-83. PubMed ID: 26573069 [TBL] [Abstract][Full Text] [Related]
14. Pazopanib a tyrosine kinase inhibitor with strong anti-angiogenetic activity: a new treatment for metastatic soft tissue sarcoma. Ranieri G; Mammì M; Donato Di Paola E; Russo E; Gallelli L; Citraro R; Gadaleta CD; Marech I; Ammendola M; De Sarro G Crit Rev Oncol Hematol; 2014 Feb; 89(2):322-9. PubMed ID: 24041629 [TBL] [Abstract][Full Text] [Related]
15. [Evidence-based treatment of gastrointestinal stromal tumor (GIST) with tyrosine kinase inhibitors-imatinib and sunitinib]. Nishida T; Omori T; Ueshima S Gan To Kagaku Ryoho; 2011 May; 38(5):733-7. PubMed ID: 21566432 [TBL] [Abstract][Full Text] [Related]
18. Regorafenib for the Treatment of Sarcoma. Blay JY; Duffaud F; George S; Maki RG; Penel N Curr Treat Options Oncol; 2022 Nov; 23(11):1477-1502. PubMed ID: 36178573 [TBL] [Abstract][Full Text] [Related]
19. Targeted therapy for cancer: the gastrointestinal stromal tumor model. Balachandran VP; Dematteo RP Surg Oncol Clin N Am; 2013 Oct; 22(4):805-21. PubMed ID: 24012400 [TBL] [Abstract][Full Text] [Related]
20. Apatinib as targeted therapy for advanced bone and soft tissue sarcoma: a dilemma of reversing multidrug resistance while suffering drug resistance itself. Yang QK; Chen T; Wang SQ; Zhang XJ; Yao ZX Angiogenesis; 2020 Aug; 23(3):279-298. PubMed ID: 32333216 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]